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Abstract.	NF-κB	signaling	pathway	is	a	validated	oncological	target.	
Here,	we	 applied	 scaffold	 hopping	 to	 IMD-0354,	 a	 presumed	 IKKβ	
inhibitor,	 and	 identified	 4-hydroxy-N-[3,5-
bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide	(4)	as	a	
nM-inhibitor	 of	 the	 NF-κB	 pathway.	 However,	 both	 4	 and	 IMD-
0354,	being	potent	inhibitors	of	the	canonical	NF-κB	pathway,	were	
found	to	be	inactive	in	human	IKKβ	enzyme	assays.	
NF-κB	 is	 a	 ubiquitously	 expressed	 family	 of	 transcription	
factors,	known	to	be	key	regulators	of	 immune	response,	cell	
proliferation,	 cell	 death	 and	 inflammation.1	NF-kB	dimers	 are	
normally	inhibited	in	the	cytoplasm	of	resting	cells	by	proteins	
called	 IκB.	 Following	 cell	 stimulation,	 the	 inhibitory	 IκB	
proteins	 are	 rapidly	 phosphorylated	 by	 the	 so-called	 IKK	
kinases,	 and	 subsequently	 degraded	 by	 the	 26S	 proteasome.	
This	 is	 followed	 by	 the	 translocation	 of	 the	 transcription	
factors	 to	 the	 nuclei	 and	 subsequent	 activation	 of	 the	
corresponding	 gene	 expression	 (the	 so-called	 canonical	
pathway	of	NF-κB	activation).	NF-κB	signaling	has	been	found	
to	 be	 constitutively	 activated	 in	 a	 variety	 of	 malignancies,	
leading	 to	uncontrolled	apoptosis,	 cell	 cycle	deregulation	and	
metastatic	 growth.1	 These	 observations	 validated	 the	 NF-κB	
pathway	 as	 an	 oncologic	 target,	 in	 particular	 in	 breast2	 and	
thyroid	 cancer.3	 The	 trimeric	 IKK	 complex	 involved	 in	 the	
activation	 of	 the	 canonical	 NF-κB	 pathway	 contains	 two	
catalytic	 subunits,	 IKKα	 and	 IKKβ	 kinase,	 and	 a	 regulatory	
protein	 IKKγ	 (also	 called	 NEMO).	 In	 a	 parallel,	 so-called	 non-
canonical	 pathway,4	 TNF-receptor	 superfamily	 members	
selectively	 activate	 a	 different	 set	 of	 kinases,	 NF-κB-inducing	
kinase	(NIK)	and	IκB	kinase	1	(IKK1).4	
The	 efforts	 aimed	 at	 discovering	 new	 NF-κB	 inhibitors,	 and	
particularly	 inhibitors	of	 IKKβ,	have	been	 intensified	 in	 recent	
years.5	 Recently,	 the	 X-ray	 structures	 of	 IKKβ	 in	 a	 ligand-free	
form	and	in	complex	with	an	inhibitor	have	been	reported,6,	7	
thus	providing	new	opportunities	for	the	design	of	new	potent	
inhibitors.1	 Although	 no	 IKKβ	 inhibitors	 have	 reached	 the	
human	 pharmacopoeia	 yet,	 some	 interesting	molecules	 have	
been	studied.	Among	those	is	PS-1145	(Figure	1),	a	β-carboline	
analogue	 known	 to	 potently	 and	 selectively	 inhibit	 the	
endogenous	 IKK	 complex	 with	 an	 IC50	 of	 150	 nM.
8-10	 Other	
examples	 include,	 BMS-345541	 11	 which	 acts	 by	 allosterically	
inhibiting	 IKKβ,	 and	 IMD-0354,	 which	 reached	 the	 stage	 of	
clinical	 trials12	 (Figure	 1).	 IMD-0354	 was	 designed	 by	 the	
Institute	of	Medicinal	Molecular	Design	Inc	(Tokyo,	Japan)	and	
is	claimed	to	be	a	selective	inhibitor	of	 IKKβ.13	The	compound	
has	 completed	phase	1	 clinical	 trials	 as	an	anti-inflammatory,	
anti-allergic	 and	 anti–microbial	 agent,14	 while	 its	 prodrug,	
called	 IMD-104115	 was	 evaluated	 in	 clinical	 trials	 that	 are	
currently	awaiting	proof-of-concept	results	(NCT00883584).14	
	
Figure	1:	PS-1145,	BMS-345541	and	IMD-0354	as	examples	of	
IKKβ	inhibitors.	
	
The	 biological	 activity	 of	 IMD-0354	 has	 been	 described	 in	 a	
variety	 of	 assays	 related	 to	 metabolic	 diseases	 and	
cardiovascular	diseases.15-27	In	particular,	it	has	been	reported	
that	IMD-0354	is	able	to	suppresses	neoplastic	proliferation	of	
human	mast	cells	with	constitutively	activated	c-kit	receptor,28	
and	inhibits	the	growth	of	human	breast	cancer	cells	MDA-MB-
231,	HMC1-8	and	MCF-7.29		
Bio(iso)steric	 replacement	 is	 a	 widely	 used	 approach	 in	
medicinal	chemistry,	aimed	at	improving	the	characteristics	of	
a	 lead	 compound,	 such	 as	 bioavailability,	 selectivity,	 and	
potency.30	 As	 an	 example	 of	 the	 use	 of	 the	 method,	 we	
recently	 designed	 a	 new	 generation	 of	 potent	 hDHODH	
inhibitors31	 using	 hydroxylated	 azoles.	 In	 these	 systems,	 the	
substitution	 of	 the	 azole	 ring	 allowed	 fine-tuning	 of	 the	
accessible	chemical	space,32	 thus	 increasing	the	probability	of	
triggering	 the	 desired	 change	 in	 biological	 activity.	 Here,	 we	
applied	 a	 similar	 approach	 to	 the	 phenolic	 substructure	 in	
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IMD-0354	to	design	new	IKKβ	inhibitors.	The	compounds	1	to	
11	 (Figure	 2)	 have	 been	 designed	 using	 four	 different	 acidic	
azoles:	hydroxyoxadiazole,	hydroxythiadiazole,	hydroxytriazole	
and	 hydroxypyrazole.	 The	 four	 hydroxyazole	 systems	 have	
been	selected	to	bioisosterically	modulate	the	phenolic	moiety	
of	 IMD-0354	 by	 their	 different	 acidic	 and	 lipophilic	
properties.33	 Notably,	 hydroxytriazole	 and	 hydroxypyrazole	
scaffolds	 can	 be	 modified	 by	 the	 addition	 of	 protruding	
substituents,	 which	 may	 be	 designed	 to	 occupy	 the	
surrounding	 chemical	 space	 in	 several	 directions.	 Schemes	 1	
and	 2	 outline	 the	 synthetic	 methodologies	 used	 for	 the	
preparation	of	the	target	compounds	1	-	11.	
	
Scheme	1.	Synthesis	of	1,2,5-oxadiazole	and	thiadiazole	analogues	1	-	
6:	 i)	 a)	 oxalyl	 chloride,	 DMF,	 dry	 THF,	 b)	 substituted	 aniline,	 dry	
pyridine,	 dry	 THF;	 ii)	 H2,	 Pd/C,	 dry	 THF;	 iii)	 CH3I,	 Cs2CO3,	 dry	 THF;	 iv)	
HBTU,	DMAP,	3,5-bis(trifluoromethyl)aniline,	dry	DMF.	
	
Figure	2:	The	bioisosteric	scaffold	hopping	strategy	applied	to	
IMD-0354	 using	 hydroxyoxadiazole,	 hydroxythiadiazole,	
hydroxytriazole	and	hydroxypyrazole	scaffolds.	
	
In	some	cases,	a	benzyloxy-protected	azolecarboxylate	(12,	16,	
20)	 was	 transformed	 into	 the	 corresponding	 acyl	 chloride,	
which	was	allowed	to	react	with	the	appropriate	aniline,	thus	
obtaining	 the	 corresponding	 amide	 (compounds	 13,	 17	 and	
21).	 The	 removal	 of	 the	 protecting	 benzyl	 group	 was	
accomplished	 by	 applying	 room	 pressure	 hydrogenation	
conditions	(1,	2,	7,	8,	10,	11).	In	the	case	of	triazole	analogue	9	
(scheme	 2),	 the	 coupling	 reaction	 was	 conducted	 on	 the	 p-
methoxybenzyl	 protected	 precursor	 18,	 previously	 obtained	
from	 its	 corresponding	 ethyl	 ester.33	 The	 resulting	 amide	 19	
was	then	deprotected	under	acidic		conditions	(TFA).		
Scheme	2.	Synthesis	of	 triazole	and	pyrazole	analogues	 (7	–	11).	 i)	a)	
oxalyl	 chloride,	 DMF,	 dry	 THF;	 b)	 3,5-bis(trifluoromethyl)aniline,	 dry	
pyridine,	dry	THF;	ii)	H2,	Pd/C,	dry	THF;	iii)	TFA,	45°C.	
	
Other	 compounds	 (4,	 5	 and	 3,	 scheme	 1)	 were	 obtained	 by	
coupling	 unprotected	 4-hydroxythiadiazole-3-carboxylic	 acyl	
chloride	 of	 the	 corresponding	 acid	 1434	 or	 commercial	
available	 4-aminofurazan-3-carboxylic	 acid	 15	 with	 the	
corresponding	aniline.	Compound	4	was	then	methylated	with	
methyl	 iodide	 to	 obtain	 compound	 6.	 Synthetic	 procedures	
and	spectral	characterization	of	the	final	compounds	1	-	11	are	
shown	in	the	supplementary	material.	
The	 designed	 compounds	 1	 –	 11	 (Figure	 2)	 were	 evaluated	
both	by	enzymatic	and	cellular	 assays	and	compared	 to	 IMD-
035435	 and	 PS-1145,36	 the	 latter	 used	 as	 IKKβ	 reference	
inhibitor8	(Table	1).		
	
Compound	
IKKβ	
IC50	±	SE	
(µM)	
(%	inhib	at	
100	μM)a	
IKKα		
IC50	±	SE	
(µM)	
(%	inhib	at	
100	μM)	a	
IKKε	
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(µM)	
(%	inhib	at	
100	μM)	a	
NIK	
IC50	±	SE	
(µM)	
(%	inhib	at	
100	μM)	a	
IC50	(µM)	on	
IκBα 	
degradation	
assayb	
IMD-0354	 >100	(5.43)	
>100	
(3.45)	
>100	
(30.5)	
>100	
(13.8)	 0.218±0.007	
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PS-1145	 0.087±0.005	 >100	 >100	 >100	 0.186±0.008	
1	 >100	(12.2)	
>100	
(18.6)	
58.5±0.4	 >100	
(19.3)	
6.93±0.12	
2	 >100	(2.06)	
>100	
(-2.5)	
>100	
(32.1)	
>100	
(11.8)	 1.72±0.11	
3	 >100	(31.59)	
>100	
(29.3)	 44.8±0.8	
>100	
(-9.2)	 >100	
4	 >100	(-10.32)	
>100	
(25.2)	
>100	
(30.2)	
>100	
(4.34)	 0.143±0.005	
5	 >100	(-0.94)	 35.5±0.6	
>100	
(25.8)	
>100	
(-1.1)	 >100	
6	 >100	(8.51)	
>100	
(24.1)	
>100	
(21.9)	
>100	
(-1.9)	 >100	
7	 >100	(5.19)	
>100	
(46.9)	
>100	
(6.9)	
>100	
(9.1)	
>100	
8	 >100	(11.2)	
>100	
(13.1)	 58.5±0.3	
>100	
(12.1)	 >100	
9	 >100	(5.14)	
>100	
(24.5)	
>100	
(15.3)	
>100	
(-9.5)	
>100	
10	 >100	(12.7)	
>100	
(12.1)	
>100	
(17.2)	
>100	
(7.23)	 25.9±0.4	
11	 >100	(13.9)	
>100	
(13.2)	
>100	
(14.2)	
>100	
(24.1)	 1.32±0.21	
Table	 1.	 The	 effects	 of	 IMD-0354,	 PS-1145	 and	 the	 designed	
compounds	on:	a)	ATP-based	kinase	assays	for	IKKβ,	IKKα,	IKKε	
and	 NIK	 (expressed	 as	 IC50	 value,	 μM);	
b)	 IĸBα	 degradation	
assay	 in	 Jurkat	 cells	 (expressed	 as	 IC50	 value,	 μM).	 All	
experiments	were	performed	 in	triplicate,	and	data	represent	
means	±	standard	deviation	(SD).	
	
At	 the	 enzymatic	 level,	 the	 activity	 was	 assessed	 on	
recombinant	human	 IKKβ.	Surprisingly,	 the	 IMD-0354	 lead,	as	
well	 as	 the	 designed	 compounds	 1	 -	 11,	 were	 found	 to	 be	
inactive	in	the	assays	(Table	1).	This	result	does	not	agree	with	
the	earlier	proposed	mechanism	of	action	of	IMD-0354,	which	
assumes	that	the	compound	is	a	potent	inhibitor	of	IKKβ.28,	29,	
37	In	particular,	its	molecular	structure	was	originally	designed	
by	 analysing	 the	 binding	mode	 of	aspirin	 to	 IKKβ	 at	 the	 APB	
IKK-2	 binding	 site,28	 and	 based	 on	 that	 it	 was	 suggested	 to	
compete	with	 ATP	 for	 binding	 to	 IKKβ.38	 Based	 on	 an	NF-κB-
IKKβ	 reporter	 assay	 that	 uses	 a	 constitutively	 active	 IKKβ	
mutant,17	the	compound’s	mechanism	of	action	was	suggested	
to	involve	the	inhibition	of	phosphorylation	of	IκB.	
Indeed,	 IMD-0354	 was	 found	 to	 inhibit	 the	 activated	
expression	 of	 NF-kB	 in	 a	 dose-dependent	 manner	 in	 HepG2	
cells	 transfected	with	pFLAG-CMV-IKKβ	 (S177E/S181E)	vector,	
and	 subsequent	 verification	 of	 IκBα	 degradation	 by	Western	
blot	 analysis	 of	 cytosolic	 phospho-IκBα.	 The	 authors	
concluded17	 that	 the	 results	 were	 consistent	 with	 IKKβ	
inhibition	 although	 IMD-0354	 was	 not	 assayed	 on	 isolated	
enzyme.	 In	 recent	 years,	 Azucena	 Gomez-Cabrero	 et	 al39	
defined	IMD-0354	as	“an	indirect	inhibitor	of	NF-κB”,	probably	
due	to	the	 lack	of	strong	evidence	supporting	an	IKKβ	related	
mechanism.	In	order	to	get	a	broader	overview	of	the	action	of	
IMD-0354,	we	assayed	both	IMD-0354	and	PS-1145,	as	well	as	
compounds	1	-	11,	against	the	other	three	kinases	involved	in	
the	 canonical	 and	 non-canonical	 NF-κB	 activation	 pathways	
(IKKα,	 IKKε	 and	 NIK).	 In	 this	 assay	 the	 newly	 synthesized	
compounds	 and	 IMD-0354	 were	 found	 to	 be	 essentially	
inactive	(only	modest	activity	of	compounds	1,	3	and	5	 in	the	
μM	range	was	observed,	Table	1).	
Since	IMD-0354	has	been	described	as	potent	 inhibitor	of	the	
NF-ĸB	pathway	in	cellular	assays,	we	also	evaluated	the	ability	
of	 IMD-0354	 and	 compounds	 1	 -	 11	 to	 block	 the	 NF-κB	
pathway.	In	these	experiments	the	capacity	of	the	compounds	
to	inhibit	the	degradation	of	IκBα	after	inflammatory	stimulus	
was	 evaluated	 in	 Jurkat	 cells.	 In	 agreement	 with	 earlier	
results,17	these	assays	showed	IMD-0354	to	be	a	potent	NF-κB	
inhibitor	 with	 IC50	 =	 0.218	 μM	 (Table	 2).	 Among	 the	 new	
compounds,	 the	 hydroxythiadiazole	 4	 was	 the	 most	 active,	
with	IC50	of	0.143	μM	(Table	1	and	Figure	3).	Compounds	1,	2,	
10	and	11	were	active	in	the	low	μM	range.	
		
Figure	3.	Effects	of	compound	4	on	IκBα	degradation	in	Jurkat	
cells	 stimulated	 by	 TNF-α.	 IκBα	 protein	 expression	 was	
evaluated	by	immunoblotting.	One	representative	immunoblot	
of	three	independent	experiments	is	shown.	Graphs	represent	
IκBα	 relative	 band	 intensity	 quantified	 by	 densitometric	
analysis	after	normalization	using	β-actin	as	reference.	Values	
are	means	±	SD	of	three	independent	experiments.	
	
The	effects	of	 PS-1145,	 IMD-0354	and	 compound	4	on	NF-κB	
gene	 reporter	 assay	 in	 Jurkat	 (TIB-152,	 ATCC)	 and	MDA-MB-
231	(ACC-732,	DSMZ)	cells	were	also	evaluated	(Figure	4).	
	
		
Figure	 4.	 Effects	 of	 PS-1145,	 IMD-0354	 and	 compound	 4	 on	
NF-κB	gene	reporter	assay	in	Jurkat	and	MDA-MB-231	cells.		
	
All	 three	 compounds	 were	 found	 active	 on	 TNFα-activated	
Jurkat	cells	6h	post-treatment,	with	compound	4	having	higher	
potency	than	IMD-0354	and	PS-1145	(residual	activity	at	1	μM:	
IMD-0354,	23.48	%;	PS-1145,	38.14	%;	4,	 15.91	%).	However,	
both	 compounds	 4	 and	 IMD-0354	 were	 almost	 completely	
inactive	 on	 MDA-MB-231	 cells	 6h	 post-treatment	 (residual	
activity	at	10	μM:	 IMD-0354,	98.99	%;	compound	4,	96.08	%)	
and	 showed	 an	 appreciable	 activity	 24h	 post-treatment	
(residual	activity	at	10	μM:	 IMD-0354,	58.27	%;	 compound	4,	
63.01	%).	 Conversely,	 10	µM	PS-1145	 showed	potent	 activity	
not	 only	 at	 24h	 but	 also	 at	 6h	 (residual	 activity	 at	 10	 μM:	
19.52%	(6	h)	and	8.67%	(24	h)).	The	different	inhibitory	activity	
showed	of	IMD-0354	and	compound	4	in	gene	reporter	assay,	
carried-out	 in	 Jurkat	 and	 MDA-MB-231	 cells,	 is	 probably	 a	
consequence	of	the	activation	status	of	the	NF-kB	pathway.	In	
fact,	 in	 Jurkat	 cells	 the	NF-κB	pathway	was	activated	 through	
the	treatment	with	TNFα	whilst	 in	MDA-MB-231	cells	 the	NF-
κB	 signaling	 pathway	 was	 reported	 to	 be	 constitutively	
activated	and	driven	by	both	IKKβ	and	IKKα.40		
The	anti-inflammatory	effects	of	compound	4	were	evaluated	
in	LPS-stimulated	THP-1	(ACC-16,	DSMZ)	in	which	the	canonical	
NF-κB	 signaling	 pathway	 controls	 the	 expression	 of	 several	
pro-inflammatory	 cytokines.41	 Compound	 4	 prevented	 in	 a	
dose-dependent	manner	the	LPS-induced	degradation	of	 IκBα	
(Figure	5).	
Figure	 5.	 Effects	 of	 compound	 4,	 IMD-0354,	 PS-1145,	 aspirin	
(ASA)	 and	 indomethacin	 (Indo)	 on	 IκBα	 degradation	 in	 THP-1	
cells	stimulated	by	LPS.	IκBα	protein	expression	was	evaluated	
by	 immunoblotting.	One	 representative	 immunoblot	 of	 three	
independent	experiments	is	shown.		
	
These	 results	 also	 agree	 with	 earlier	 experiments,	 which	
showed	 that	 IMD-0354	 is	 able	 to	 specifically	 block	 the	NF-ĸB	
pathway	when	induced	by	proinflammatory	cytokines,	such	as	
TNFα	 and	 IL-1β.15,	 29	 The	 presented	 experiments	 show	 that	
compound	4	potently	blocks	the	NF-kB	cascade,	particularly	in	
conditions	of	TNFα	activation.	However,	similarly	to	IMD-0354,	
compound	4	does	not	inhibit	IKKβ	at	enzymatic	level	(Table	1).	
For	a	better	understanding	of	 the	possible	role	of	 IKKβ	 in	 the	
IMD-0354	 mechanism	 of	 action,	 we	 assayed	 the	 compound	
against	 the	 trimeric	 IKKβ-IKKα-Nemo	 complex,	 isolated	 from	
Jurkat	cells	treated	with	TNFα.	In	this	assay,	IMD-0354	showed	
only	 weak	 activity	 (40	 %	 inhibition	 at	 100	 µM,	 see	
Supplementary),	which	does	not	 explain	 the	 claimed	potency	
of	 the	 compound	 on	 the	NF-κB	 cascade.	Moreover,	 in	 Jurkat	
cells	exposed	to	IMD-0354	and	treated	with	TNFα,	the	IKKs	of	
the	 trimeric	 complex	 were	 found	 to	 be	 phosphorylated	
(Supplementary),	 indicating	 that	 the	 TNFα	 stimulus	 did	 reach	
them.	These	 results	 suggest	 that	 the	mechanism	of	 inhibition	
of	the	canonical	NF-κB	pathway	by	IMD-0354	is	probably	more	
complex	than	it	was	thought.	However,	the	elucidation	of	this	
mechanism	is	outside	the	scope	of	this	publication.	
Finally,	 we	 also	 studied	 antiproliferative	 activity	 and	
cytotoxicity	of	compounds	4	on	MDA-MB-231	cells,	comparing	
them	to	IMD-0354	and	PS-1145	(Table	2).	Quantitation	of	DNA	
content	 and	 a	 fluorescent	 assay	 to	 assess	 cell	 membrane	
integrity	 were	 used	 to	 evaluate	 cell	 proliferation	 and	
cytotoxicity	,	respectively.	
	
Compound	 Antiproliferative	effect	IC50	±	SE	(µM)	
Cytotoxicity	
IC50	±	SE	(µM)	
4	 1.29±0.08	 53±2	
IMD-0354	 0.64±0.04	 0.85±0.01	
PS-1145	 0.90±0.07	 >100	
Table	2.	Antiproliferative	and	cytotoxic	effects	of	compound	4,	
IMD-0354	 and	 PS-1145	 on	 MDA-MB-231	 cells.	 Cells	 were	
exposed	 to	 inhibitors	 for	 72	 h.	 Data	 obtained	 for	 IMD-0354	
agree	with	previously	reported	results.29	Data	obtained	for	PS-
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1145	agree	with	previously	reported	antiproliferation	assays	in	
MDA-MB-231	cells.40	
It	can	be	seen	from	the	data	 in	Table	2	that	compound	4	has	
antiproliferative	effect	in	the	low	µM	range	(1.29	µM),	slightly	
lower	 than	 that	 of	 the	 two	 lead	 compounds.	 On	 the	 other	
hand,	this	compound	is	not	cytotoxic	as	IMD-0354,	showing	an	
effect	more	 reminiscent	of	 that	of	PS-1145,	able	 to	block	 the	
NF-kB	 cascade	 without	 significant	 cytotoxicity.	 In	 contrast	 to	
compound	 4	 and	 PS-1145,	 IMD-0354	 has	 similar	 IC50	 in	 both	
proliferation	and	cytotoxicity	assays.	
	
In	conclusion,	here	we	introduce	the	hydroxythiadiazole	4	as	a	
nanomolar	 inhibitor	 of	 the	 canonical	 NF-kB	 cascade.	 The	
compound	 was	 designed	 through	 a	 bioisosteric	 scaffold	
hopping	approach	applied	to	the	phenolic	moiety	of	IMD-0354.	
When	 compared	 to	 IMD-0354,	 compound	 4	 showed	 similar	
mode	of	action,	although	with	higher	potency	 in	blocking	 the	
NF-kB	cascade	on	Jurkat	cells	and	 lower	cytotoxicity	on	MDA-
MB-231	cells.	Both	4	and	the	 lead	 IMD0354	were	found	to	be	
inactive	in	IKKβ	enzymatic	assays,	although	both	being	able	to	
inhibit	 the	 canonical	 NF-kB	 pathway	 after	 TNFα	 or	 LPS	
stimulus.	
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